Huguette Albrecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huguette Albrecht has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Sally J. DeNardo
Cancer Center, University of California, Davis Medical Center, Sacramento, CA
3 shared publications- David M. Rocke
Department of Public Health Sciences University of California Davis
2 shared publications Gerald L. DeNardo
Cancer Center, University of California, Davis Medical Center, Sacramento, CA
2 shared publicationsKaren M. Kalanetra
Department of Public Health Sciences University of California at Davis School of Medicine One Shields Avenue 95616 Davis CA USA
2 shared publicationsReem Yunis
Department of Public Health Sciences, University of California at Davis School of Medicine, One Shields Avenue, Davis, CA 95616, USA
2 shared publicationsShiquan Wu
Department of Public Health Sciences University of California at Davis School of Medicine One Shields Avenue 95616 Davis CA USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in BMC Plant Biology
- Vol. 13 (1) , 28
The differentially regulated genes TvQR1 and TvPirin of the parasitic plant Triphysaria exhibit distinctive natural allelic diversity
Plant parasitism represents an extraordinary interaction among flowering plants: parasitic plants use a specialized organ, the haustorium, to invade the host vascular system to deprive host plants of water and nutrients. Various compounds present in exudates of host plants trigger haustorium development. The two most effective haustorium inducing factors (HIFs) known for the parasitic plant Triphysaria versicolor (T. versicolor) are peonidin, an antioxidant flavonoid, and 2,6-dimethoxybenzoquinone (DMBQ), an oxidative stress agent. To date, two genes involved in haustorium initiation in T. versicolor have been identified: TvQR1, a quinone oxidoreductase that generates the active HIF from DMBQ, and TvPirin, a transcription co-factor that regulates several other DMBQ- responsive and –non-responsive genes. While the expression of these genes in response to DMBQ is well characterized, their expression in response to peonidin is not. In addition, the pattern of polymorphisms in these genes is unknown, even though nucleotide changes in TvQR1 and TvPirin may have contributed to the ability of T. versicolor to develop haustoria. To gain insights into these aspects, we investigated their transcriptional responses to HIFs and non-HIF and their natural nucleotide diversity.
- 1 January 2013
- Published by Springer Nature in BMC Plant Biology
- Vol. 13 (1) , 28
Open AccessThe differentially regulated genes TvQR1 and TvPirin of the parasitic plant Triphysaria exhibit distinctive natural allelic diversity
Plant parasitism represents an extraordinary interaction among flowering plants: parasitic plants use a specialized organ, the haustorium, to invade the host vascular system to deprive host plants of water and nutrients. Various compounds present in exudates of host plants trigger haustorium development. The two most effective haustorium inducing factors (HIFs) known for the parasitic plant Triphysaria versicolor (T. versicolor) are peonidin, an antioxidant flavonoid, and 2,6-dimethoxybenzoquinone (DMBQ), an oxidative stress agent. To date, two genes involved in haustorium initiation in T. versicolor have been identified: TvQR1, a quinone oxidoreductase that generates the active HIF from DMBQ, and TvPirin, a transcription co-factor that regulates several other DMBQ- responsive and –non-responsive genes. While the expression of these genes in response to DMBQ is well characterized, their expression in response to peonidin is not. In addition, the pattern of polymorphisms in these genes is unknown, even though nucleotide changes in TvQR1 and TvPirin may have contributed to the ability of T. versicolor to develop haustoria. To gain insights into these aspects, we investigated their transcriptional responses to HIFs and non-HIF and their natural nucleotide diversity.
- Open Access
- 21 August 2012
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 53 (6) , 860-875
Genomic characterization of a three-dimensional skin model following exposure to ionizing radiation
This study aimed at characterizing the genomic response to low versus moderate doses of ionizing radiation (LDIR versus MDIR) in a three-dimensional (3D) skin model, which exhibits a closer tissue complexity to human skin than monolayer cell cultures. EpiDermFT skin plugs were exposed to 0, 0.1 and 1 Gy doses of X-rays and harvested at 5 min, 3, 8 and 24 h post-irradiation (post-IR). RNA was interrogated for global gene expression alteration. Our results show that MDIR modulated a larger number of genes over the course of 24 h compared to LDIR. However, immediately and throughout the first 3h post-IR, LDIR modulated a larger number of genes than MDIR, mostly associated with cell-cell signaling and survival promotion. Significant modulation of pathways was detected only at 3 h post-IR in MDIR with induction of genes promoting apoptosis. Collectively, the data show different dynamics in the response to LDIR versus MDIR, especially in cell-cycle distribution. LDIR-exposed tissues showed signs of attempted cell-cycle re-entry as early as 3 h post-IR, but were arrested beyond 8 h at the G1/S checkpoint. At 24 h, cells appeared to accumulate at the G2/M checkpoint. MDIR-exposed tissues did not exhibit a prolonged G1/S arrest but rather a prolonged G2/M arrest, which was sustained at least up to 24 h. By 24 h cells exhibited signs of recovery in both LDIR- and MDIR-exposed tissues. In summary, the most pronounced difference in the initial cellular response to LDIR versus MDIR is the promotion of protection and survival in LDIR versus the promotion of apoptosis in MDIR.
- 21 August 2012
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 53 (6) , 860-875
Open AccessGenomic characterization of a three-dimensional skin model following exposure to ionizing radiation
This study aimed at characterizing the genomic response to low versus moderate doses of ionizing radiation (LDIR versus MDIR) in a three-dimensional (3D) skin model, which exhibits a closer tissue complexity to human skin than monolayer cell cultures. EpiDermFT skin plugs were exposed to 0, 0.1 and 1 Gy doses of X-rays and harvested at 5 min, 3, 8 and 24 h post-irradiation (post-IR). RNA was interrogated for global gene expression alteration. Our results show that MDIR modulated a larger number of genes over the course of 24 h compared to LDIR. However, immediately and throughout the first 3h post-IR, LDIR modulated a larger number of genes than MDIR, mostly associated with cell-cell signaling and survival promotion. Significant modulation of pathways was detected only at 3 h post-IR in MDIR with induction of genes promoting apoptosis. Collectively, the data show different dynamics in the response to LDIR versus MDIR, especially in cell-cycle distribution. LDIR-exposed tissues showed signs of attempted cell-cycle re-entry as early as 3 h post-IR, but were arrested beyond 8 h at the G1/S checkpoint. At 24 h, cells appeared to accumulate at the G2/M checkpoint. MDIR-exposed tissues did not exhibit a prolonged G1/S arrest but rather a prolonged G2/M arrest, which was sustained at least up to 24 h. By 24 h cells exhibited signs of recovery in both LDIR- and MDIR-exposed tissues. In summary, the most pronounced difference in the initial cellular response to LDIR versus MDIR is the promotion of protection and survival in LDIR versus the promotion of apoptosis in MDIR.
- 1 July 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (7) , 671-674
Concurrent HER2 Vaccination and Inhibition of Kinase Activity: Safety and Immunogenicity
Passive immunotherapy with the monoclonal antibody trastuzumab and tyrosine kinase activity inhibition with lapatinib are HER2-targeted therapies used in the clinic for the treatment of HER2-overexpressing breast cancers. Unfortunately, the therapeutic efficacy of both these therapies is abolished by primary and acquired tumor resistance. Active immunotherapy against HER2, which, thanks to trastuzumab, is a clinically validated tumor-associated antigen, might provide an alternative therapeutic strategy for HER2-overexpressing breast cancers. This Phase I study of HER2 immunotherapy with concomitant lapatinib treatment in 12 patients with metastatic breast cancer resistant to trastuzumab demonstrates the feasibility and safety of concurrent vaccination against HER2 and inhibition of HER1 and HER2 kinases. However, it is inconclusive regarding the effect of lapatinib on the immune responses induced by dHER2/AS15; vaccination triggered variable levels of anti-HER2 antibodies in all the patients, but a HER2-specific T-cell response was detected in one patient only. Since the presence of Tregs in these patients was not assessed, it remains unclear whether lapatinib and/or Tregs account for the near absence of a T-cell response.
- 1 July 2012
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (7) , 671-674
Concurrent HER2 Vaccination and Inhibition of Kinase Activity: Safety and Immunogenicity
Passive immunotherapy with the monoclonal antibody trastuzumab and tyrosine kinase activity inhibition with lapatinib are HER2-targeted therapies used in the clinic for the treatment of HER2-overexpressing breast cancers. Unfortunately, the therapeutic efficacy of both these therapies is abolished by primary and acquired tumor resistance. Active immunotherapy against HER2, which, thanks to trastuzumab, is a clinically validated tumor-associated antigen, might provide an alternative therapeutic strategy for HER2-overexpressing breast cancers. This Phase I study of HER2 immunotherapy with concomitant lapatinib treatment in 12 patients with metastatic breast cancer resistant to trastuzumab demonstrates the feasibility and safety of concurrent vaccination against HER2 and inhibition of HER1 and HER2 kinases. However, it is inconclusive regarding the effect of lapatinib on the immune responses induced by dHER2/AS15; vaccination triggered variable levels of anti-HER2 antibodies in all the patients, but a HER2-specific T-cell response was detected in one patient only. Since the presence of Tregs in these patients was not assessed, it remains unclear whether lapatinib and/or Tregs account for the near absence of a T-cell response.
- 1 January 2012
- Published by Radiation Research Society in Radiation Research
- Vol. 177 (1) , 69-83
Transcriptional Response ofEx VivoHuman Skin to Ionizing Radiation: Comparison Between Low- and High-Dose Effects
Although human exposure to low-dose ionizing radiation can occur through a variety of sources, including natural, medical, occupational and accidental, the true risks of low-dose ionizing radiation are still poorly understood in humans. Here, the global transcriptional responses of human skin after ex vivo exposure to low (0.05 Gy) and high (5 Gy) doses of X rays and of time in culture (0 Gy) at 0, 2, 8 and 30 h postirradiation were analyzed and compared. Responses to low and high doses differed quantitatively and qualitatively. Differentially expressed genes fell into three groups: (1) unique genes defined as responsive to either 0.05 or 5 Gy but not both and also responsive to time in culture, (2) specific genes defined as responsive to either 0.05 or 5 Gy but not both and not responsive to time in culture, and (3) dose-independent responsive genes. Major differences observed in ex vivo irradiated skin between transcriptional responses to low or high doses were twofold. First, gene expression modulated by 0.05 Gy was transient, while in response to 5 Gy persistence of modified gene expression was observed for a limited number of genes. Second, neither TP53 nor TGFβ target genes were modulated after exposure to an acute low dose, suggesting that the TP53-dependent DNA damage response either was not triggered or was triggered only briefly.
- 1 January 2012
- Published by Radiation Research Society in Radiation Research
- Vol. 177 (1) , 69-83
Transcriptional Response ofEx VivoHuman Skin to Ionizing Radiation: Comparison Between Low- and High-Dose Effects
Although human exposure to low-dose ionizing radiation can occur through a variety of sources, including natural, medical, occupational and accidental, the true risks of low-dose ionizing radiation are still poorly understood in humans. Here, the global transcriptional responses of human skin after ex vivo exposure to low (0.05 Gy) and high (5 Gy) doses of X rays and of time in culture (0 Gy) at 0, 2, 8 and 30 h postirradiation were analyzed and compared. Responses to low and high doses differed quantitatively and qualitatively. Differentially expressed genes fell into three groups: (1) unique genes defined as responsive to either 0.05 or 5 Gy but not both and also responsive to time in culture, (2) specific genes defined as responsive to either 0.05 or 5 Gy but not both and not responsive to time in culture, and (3) dose-independent responsive genes. Major differences observed in ex vivo irradiated skin between transcriptional responses to low or high doses were twofold. First, gene expression modulated by 0.05 Gy was transient, while in response to 5 Gy persistence of modified gene expression was observed for a limited number of genes. Second, neither TP53 nor TGFβ target genes were modulated after exposure to an acute low dose, suggesting that the TP53-dependent DNA damage response either was not triggered or was triggered only briefly.
- 1 June 2011
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 26 (3) , 261-271
MUC1 and MUC4: Switching the Emphasis from Large to Small
The MUC1 and MUC4 membrane mucins are each composed of a large alpha (α) and a small beta (β) subunit. The α subunits are fully exposed at the cell surface and contain variable numbers of repeated amino acid sequences that are heavily glycosylated. In contrast, the β subunits are much smaller and are anchored within the cell membrane, with their amino-terminal portions exposed at the cell surface and their carboxy-terminal tails facing the cytosol. Studies over the last several years are challenging the long-held belief that α subunits play the predominant role in cancer by conferring cellular properties that allow tumor cells to evade immune recognition and destruction. Indeed, the β subunits of MUC1 and MUC4 have emerged as oncogenes, as they engage signaling pathways responsible for tumor initiation and progression. Thus, a switch in the emphasis from the large α to the small β subunits offers attractive possibilities for successful clinical application. Such a focus shift is further supported by the absence of allelic polymorphism and variable glycosylation in the β subunit as well as by the presence of the β subunit in most MUC1 and MUC4 isoforms expressed by tumors. MUC1α, also known as CA15.3, is a Food and Drug Administration-approved serum biomarker for breast cancer, but its use is no longer recommended by the American Society of Clinical Oncology. However, comparison of β subunit expression in normal and malignant breast tissues may offer a novel approach to the exploitation of membrane mucins as biomarkers, as MUC1β-induced gene signatures with prognostic and predictive values in breast cancer have been reported. Preclinical studies with peptides that interfere with MUC1β oncogenic functions also look promising.
- 1 June 2011
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 26 (3) , 261-271
MUC1 and MUC4: Switching the Emphasis from Large to Small
The MUC1 and MUC4 membrane mucins are each composed of a large alpha (α) and a small beta (β) subunit. The α subunits are fully exposed at the cell surface and contain variable numbers of repeated amino acid sequences that are heavily glycosylated. In contrast, the β subunits are much smaller and are anchored within the cell membrane, with their amino-terminal portions exposed at the cell surface and their carboxy-terminal tails facing the cytosol. Studies over the last several years are challenging the long-held belief that α subunits play the predominant role in cancer by conferring cellular properties that allow tumor cells to evade immune recognition and destruction. Indeed, the β subunits of MUC1 and MUC4 have emerged as oncogenes, as they engage signaling pathways responsible for tumor initiation and progression. Thus, a switch in the emphasis from the large α to the small β subunits offers attractive possibilities for successful clinical application. Such a focus shift is further supported by the absence of allelic polymorphism and variable glycosylation in the β subunit as well as by the presence of the β subunit in most MUC1 and MUC4 isoforms expressed by tumors. MUC1α, also known as CA15.3, is a Food and Drug Administration-approved serum biomarker for breast cancer, but its use is no longer recommended by the American Society of Clinical Oncology. However, comparison of β subunit expression in normal and malignant breast tissues may offer a novel approach to the exploitation of membrane mucins as biomarkers, as MUC1β-induced gene signatures with prognostic and predictive values in breast cancer have been reported. Preclinical studies with peptides that interfere with MUC1β oncogenic functions also look promising.
- 22 November 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (6) , 795-798
Trastuzumab (Herceptin ® ): Overcoming Resistance in HER2 -Overexpressing Breast Cancer Models
Evaluation of: Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K et al.: Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemother. Pharmacol. 66, 269-276 (2010). Trastuzumab, a humanized antibody targeted against human epidermal receptor (HER)2, is used in combination with chemotherapy to treat patients with breast cancers overexpressing HER2. Despite initial clinical responses, disease progresses in a significant proportion of patients treated with trastuzumab and chemotherapy. Evidence of resistance to trastuzumab has not deterred a widespread clinical practice in the treatment of metastatic breast cancer - at least before lapatinib entered the clinic - which consists of continued administration of trastuzumab in combination with another chemotherapeutic drug. At present, it is not known if patients benefit from this practice. The present preclinical study demonstrates that, in the MDA-MB-361 and KPL-4 HER2(+) breast cancer models, induced resistance to trastuzumab monotherapy can be overcome by a combination of trastuzumab and granulocyte colony stimulating factor or chemotherapy. The response to trastuzumab and granulocyte colony stimulating factor appears to involve the host's immune system and antibody-dependent cellular cytotoxicity. The mechanisms underlying the response to trastuzumab and chemotherapy remain unclear.
- 22 November 2010
- Published by Taylor & Francis in Immunotherapy
- Vol. 2 (6) , 795-798
Trastuzumab (Herceptin ® ): Overcoming Resistance in HER2 -Overexpressing Breast Cancer Models
Evaluation of: Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K et al.: Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy. Cancer Chemother. Pharmacol. 66, 269-276 (2010). Trastuzumab, a humanized antibody targeted against human epidermal receptor (HER)2, is used in combination with chemotherapy to treat patients with breast cancers overexpressing HER2. Despite initial clinical responses, disease progresses in a significant proportion of patients treated with trastuzumab and chemotherapy. Evidence of resistance to trastuzumab has not deterred a widespread clinical practice in the treatment of metastatic breast cancer - at least before lapatinib entered the clinic - which consists of continued administration of trastuzumab in combination with another chemotherapeutic drug. At present, it is not known if patients benefit from this practice. The present preclinical study demonstrates that, in the MDA-MB-361 and KPL-4 HER2(+) breast cancer models, induced resistance to trastuzumab monotherapy can be overcome by a combination of trastuzumab and granulocyte colony stimulating factor or chemotherapy. The response to trastuzumab and granulocyte colony stimulating factor appears to involve the host's immune system and antibody-dependent cellular cytotoxicity. The mechanisms underlying the response to trastuzumab and chemotherapy remain unclear.
- 24 November 2009
- Published by Springer Nature
- p. 135-152
Role of Antibodies in Cancer Treatment (An Overview)
- 24 November 2009
- Published by Springer Nature
- p. 135-152
Role of Antibodies in Cancer Treatment (An Overview)
- 1 August 2007
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (4) , 531-542
Recombinant Expression of the β -Subunit of HLA-DR10 for the Selection of Novel Lymphoma Targeting Molecules
Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75%. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.
- 1 August 2007
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (4) , 531-542
Recombinant Expression of the β -Subunit of HLA-DR10 for the Selection of Novel Lymphoma Targeting Molecules
Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75%. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.
- 1 August 2006
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 21 (4) , 285-304
Update : Recombinant Antibodies: From the Laboratory to the Clinic
The development of recombinant antibodies has facilitated the exploitation of the Ab-Ag interaction specificity for targeted therapies. A fully human antibody, with custom integrated designs, can be obtained in one-third the time, compared to development of antibodies by hybridoma technology. Recombinant antibodies can be tailored for specific applications, "armed" with cytotoxic agents in a controllable fashion, and used for extracellular and intracellular targeting. Multitargeted and combination therapies are rapidly evolving for the treatment of cancer. Antibody therapeutics, costly to develop and produce, have proven beneficial in the clinic.
- 1 August 2006
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 21 (4) , 285-304
Update : Recombinant Antibodies: From the Laboratory to the Clinic
The development of recombinant antibodies has facilitated the exploitation of the Ab-Ag interaction specificity for targeted therapies. A fully human antibody, with custom integrated designs, can be obtained in one-third the time, compared to development of antibodies by hybridoma technology. Recombinant antibodies can be tailored for specific applications, "armed" with cytotoxic agents in a controllable fashion, and used for extracellular and intracellular targeting. Multitargeted and combination therapies are rapidly evolving for the treatment of cancer. Antibody therapeutics, costly to develop and produce, have proven beneficial in the clinic.
- 1 March 2006
- Published by Elsevier in Journal of Immunological Methods
- Vol. 310 (1-2) , 100-116
Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility
- 1 March 2006
- Published by Elsevier in Journal of Immunological Methods
- Vol. 310 (1-2) , 100-116
Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility